abacavir
Antiinfectives for systemic use (J05)US regulatory status: approved.
pharma · HIV-1 Infection · HIV-1 infection
Gilead Sciences
Gilead Sciences Pty Limited
Gilead Sciences drug portfolio — 54 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
333 Lakeside Drive, Foster City, CA 94404, US HQ
1987 Founded
14,602 Employees
TGA registrant Type
Company details
- Status
- Public
- HQ
- 333 Lakeside Drive, Foster City, CA 94404, US
- Founded
- 1987
- Employees
- 14,602
- Programs
- 30
- Drugs
- 54
- Patents
- 0
Gilead Sciences pipeline
Portfolio lens on 54 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Gilead Sciences drug portfolio — 54 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Gilead Sciences in public FDA and regional records. Molecular target: Tubulin.
- Target
- Tubulin
- Mechanism
- Tubulin inhibitor
-
Development asset linked to Gilead Sciences in public FDA and regional records.
-
avelumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Programmed cell death 1 ligand 1.
- Target
- Programmed cell death 1 ligand 1
- Mechanism
- Programmed cell death 1 ligand 1 other
-
bictegravir
Antiinfectives for systemic use (J05)Antiinfectives for systemic use (J05) compound in Gilead Sciences's portfolio. Molecular target: Human immunodeficiency virus type 1 integrase.
- Target
- Human immunodeficiency virus type 1 integrase
- Mechanism
- Human immunodeficiency virus type 1 integrase inhibitor
-
Development asset linked to Gilead Sciences in public FDA and regional records.
-
capecitabine
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- Thymidylate synthase inhibitor
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
cobicistat
Various (V03)US regulatory status: approved. Molecular target: Cytochrome P450 3A.
- Target
- Cytochrome P450 3A
- Mechanism
- Cytochrome P450 3A inhibitor
-
covid-19 vaccine (inactivated, adjuvanted, adsorbed)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in Gilead Sciences's portfolio. Mechanism: Biological vaccine - induces immune response.
- Mechanism
- Biological vaccine - induces immune response
-
darunavir
Antiinfectives for systemic use (J05)US regulatory status: approved. Molecular target: Human immunodeficiency virus type 1 protease.
- Target
- Human immunodeficiency virus type 1 protease
- Mechanism
- Human immunodeficiency virus type 1 protease inhibitor
-
US regulatory status: approved.
-
docetaxel
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Tubulin.
- Target
- Tubulin
- Mechanism
- Tubulin inhibitor
-
dolutegravir
Antiinfectives for systemic use (J05)US regulatory status: approved.
-
Development asset linked to Gilead Sciences in public FDA and regional records. Molecular target: Human immunodeficiency virus type 1 integrase.
- Target
- Human immunodeficiency virus type 1 integrase
- Mechanism
- Human immunodeficiency virus type 1 integrase inhibitor
-
doravirine
Antiinfectives for systemic use (J05)US regulatory status: approved. Molecular target: Human immunodeficiency virus type 1 reverse transcriptase.
- Target
- Human immunodeficiency virus type 1 reverse transcriptase
- Mechanism
- Human immunodeficiency virus type 1 reverse transcriptase negative allosteric modulator
-
doxorubicin
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Gilead Sciences's portfolio. Mechanism: DNA topoisomerase II alpha inhibitor.
- Mechanism
- DNA topoisomerase II alpha inhibitor
-
elvitegravir
Antiinfectives for systemic use (J05)US regulatory status: approved. Molecular target: Human immunodeficiency virus type 1 integrase.
- Target
- Human immunodeficiency virus type 1 integrase
- Mechanism
- Human immunodeficiency virus type 1 integrase inhibitor
-
emtricitabine
Antiinfectives for systemic use (J05)US regulatory status: approved. Molecular target: Human immunodeficiency virus type 1 reverse transcriptase.
- Target
- Human immunodeficiency virus type 1 reverse transcriptase
- Mechanism
- Human immunodeficiency virus type 1 reverse transcriptase inhibitor
-
Development asset linked to Gilead Sciences in public FDA and regional records.
-
Development asset linked to Gilead Sciences in public FDA and regional records.
-
enfortumab vedotin
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Gilead Sciences's portfolio. Molecular target: Nectin-4.
- Target
- Nectin-4
- Mechanism
- Tubulin inhibitor
-
US regulatory status: approved. Mechanism: DNA polymerase (alpha/delta/epsilon) inhibitor.
- Mechanism
- DNA polymerase (alpha/delta/epsilon) inhibitor
-
Development asset linked to Gilead Sciences in public FDA and regional records.
-
Development asset linked to Gilead Sciences in public FDA and regional records.
-
Development asset linked to Gilead Sciences in public FDA and regional records. Mechanism: Mu opioid receptor agonist.
- Mechanism
- Mu opioid receptor agonist
-
idelalisib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform.
- Target
- Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform
- Mechanism
- PI3-kinase p110-delta subunit inhibitor
-
Development asset linked to Gilead Sciences in public FDA and regional records.
-
Development asset linked to Gilead Sciences in public FDA and regional records.
-
lamivudine
Antiinfectives for systemic use (J05)US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
lenacapavir
Antiinfectives for systemic use (J05)US regulatory status: approved. Molecular target: Structural capsid protein.
- Target
- Structural capsid protein
- Mechanism
- Structural capsid protein inhibitor
-
US regulatory status: approved. Molecular target: Structural capsid protein.
- Target
- Structural capsid protein
- Mechanism
- Structural capsid protein inhibitor
-
paclitaxel
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Tubulin.
- Target
- Tubulin
- Mechanism
- Tubulin inhibitor
-
pembrolizumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Programmed cell death protein 1.
- Target
- Programmed cell death protein 1
- Mechanism
- Programmed cell death protein 1 inhibitor
-
US regulatory status: approved. Molecular target: Dihydrofolate reductase.
- Target
- Dihydrofolate reductase
- Mechanism
- Thymidylate synthase inhibitor
-
US regulatory status: approved. Molecular target: Dihydrofolate reductase.
- Target
- Dihydrofolate reductase
- Mechanism
- Thymidylate synthase inhibitor
-
Development asset linked to Gilead Sciences in public FDA and regional records.
-
Development asset linked to Gilead Sciences in public FDA and regional records.
-
raltegravir
Antiinfectives for systemic use (J05)Antiinfectives for systemic use (J05) compound in Gilead Sciences's portfolio.
-
rilpivirine
Antiinfectives for systemic use (J05)US regulatory status: approved. Molecular target: Human immunodeficiency virus type 1 reverse transcriptase.
- Target
- Human immunodeficiency virus type 1 reverse transcriptase
- Mechanism
- Human immunodeficiency virus type 1 reverse transcriptase inhibitor
-
ritonavir
Antiinfectives for systemic use (J05)US regulatory status: approved. Molecular target: Cytochrome P450 3A.
- Target
- Cytochrome P450 3A
- Mechanism
- Cytochrome P450 3A inhibitor
-
sacituzumab govitecan
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Gilead Sciences's portfolio. Molecular target: DNA topoisomerase 1.
- Target
- DNA topoisomerase 1
- Mechanism
- DNA topoisomerase I inhibitor
-
Development asset linked to Gilead Sciences in public FDA and regional records.
-
Development asset linked to Gilead Sciences in public FDA and regional records.
-
Development asset linked to Gilead Sciences in public FDA and regional records.
-
Development asset linked to Gilead Sciences in public FDA and regional records.
-
Development asset linked to Gilead Sciences in public FDA and regional records.
-
Development asset linked to Gilead Sciences in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Human immunodeficiency virus type 1 reverse transcriptase.
- Target
- Human immunodeficiency virus type 1 reverse transcriptase
- Mechanism
- Human immunodeficiency virus type 1 reverse transcriptase inhibitor
-
tenofovir disoproxil
Antiinfectives for systemic use (J05)Antiinfectives for systemic use (J05) compound in Gilead Sciences's portfolio.
-
US regulatory status: approved. Molecular target: Human immunodeficiency virus type 1 reverse transcriptase.
- Target
- Human immunodeficiency virus type 1 reverse transcriptase
- Mechanism
- Human immunodeficiency virus type 1 reverse transcriptase inhibitor
-
US regulatory status: approved. Molecular target: DNA topoisomerase 1.
- Target
- DNA topoisomerase 1
- Mechanism
- DNA topoisomerase I, mitochondrial inhibitor
-
vinflunine
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Gilead Sciences's portfolio. Molecular target: Tubulin.
- Target
- Tubulin
- Mechanism
- Tubulin inhibitor